FIELD: cell biology; medicine.
SUBSTANCE: present invention relates to the field of cell biology and medicine, in particular to a method for the transfer of NK-cells to the bone marrow of a patient, and a method for the treatment of malignant neoplasm of the bone marrow. For the implementation of the specified methods, NK-cells are brought into contact with particles PM21 and/or feeding cells FC21 before the transfer of NK-cells to the body of the specified subject, and then, NK-cells are administered to the specified subject. In this case, the transfer of NK-cells to the bone marrow and, consequently, treatment is carried out due to that the specified contact of NK-cells with particles PM21 and/or feeding cells FC21 induces in NK-cells a cell mechanism inducing fucosylation of PSGL-1 on the surface of NK-cells.
EFFECT: present invention allows for the improvement of the efficiency of directed migration (homing) of NK-cells to bone marrow.
12 cl, 34 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FORMATION OF KNOCKOUT PRIMARY AND PROPAGATED HUMAN NK CELLS USING CAS9 RIBONUCLEOPROOTEINS | 2019 |
|
RU2808035C2 |
| METHOD FOR LONG-TERM CULTIVATION AND EXPANSION OF NK CELLS WITH HIGH VIABILITY AND FUNCTIONAL ACTIVITY | 2021 |
|
RU2794770C1 |
| UNIVERSAL ANTIGEN PRESENTING CELLS AND THEIR USE | 2019 |
|
RU2809113C2 |
| RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| COMPOSITIONS AND METHODS FOR BOOSTING THE EFFECTIVENESS OF ADOPTIVE CELL IMMUNOTHERAPY | 2015 |
|
RU2716716C2 |
| COMBINED CELL TRANSPLANT BASED ON LYMPHOKINE-ACTIVATED KILLERS AND DENDRITE CELLS, METHOD FOR PRODUCTION THEREOF AND METHOD FOR TREATMENT AND PROPHYLAXIS OF MALIGNANT, INFECTIVE DISEASES AND IMMUNODEFICIENT CONDITIONS | 2006 |
|
RU2309753C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| IMMUNE-INDUCING AGENT | 2017 |
|
RU2733841C2 |
